(57) Abstract:The invention relates to chemical-pharmaceutical industry, in particular to the creation and production of protivochesotocnaya medicines. The invention lies in the fact that the drug is an ointment. The composition contains the active ingredient benzyl benzoate, emulsifier and water, the emulsifier triethanolamine stearate is formed in the reaction part ointments triethanolamine thermostable and stearic acid and further comprises a polyethylene oxide 400 at a certain ratio of components. The invention is convenient to use, is retained on the skin for 4-5 days, has a high therapeutic effect and long lasting stability. table 2. The invention relates to chemical-pharmaceutical industry, in particular to the creation and production of protivochesotocnaya medicines.Known widely used in practice simple protivochesotocnaya tool based on benzyl benzoate, which represents a benzyl ester of benzoic acid (in accordance with the international nomenclature of chemical compounds IVPAC name of substance benzyl benzoate, later in those who The tool contains, wt%: the benzyl benzoate 20; soap (green or household) 2; water 78, and is an emulsion with a mild aromatic odor, which gauze or a cotton swab is rubbed into the skin (except for the scalp, face and neck). Three days after treatment the patient is clean, change the linen. If necessary, a second treatment Agent is effective, harmless to humans, contains few components and has a low cost, but its activity and stability remain no more than 5-7 days, which does not allow to develop industrial manufacturing tools. Usually it is made individually by prescription in pharmacies .The disadvantages of the prototype include:
the inconvenience of applying the emulsion on the infected areas of the body;
small retention period specified above of drug (5-7 days).The basis of the invention the goal is to create protivochesotocnaya by means of qualitative and quantitative selection of components, which would provide a comprehensive treatment of the skin, was easy to use, had a long shelf life.The problem is solved in that the proposed protivochesotocnaya tool, containing terenowy to obtain an emulsifier, and optionally contains a polyethylene oxide 400 in the following ratio of components, wt.%:
The benzyl benzoate - 10,0-20,0
Triethanolamine - 2,5-5,0
Stearic acid - 10,0-18,0
Polyethylene oxide 400 - 5,0
Purified water - the Rest
Ointment refers to benzyl benzoate emulsion ointments of type oil-in-water". Used in the composition of ointments triethanolamine thermostable and partially stearic acid formed in the reaction of triethanolamine stearate, which is an emulsifier. The remaining part of stearic acid serves as the dispersed phase in the emulsion.The polyethylene oxide 400 performs the functions of substances that contribute to the penetration of the active ingredient of the ointment in the upper layers of the epidermis.All components offered medicines are either liquids or low-melting substances with a melting point: benzyl benzoate +18oWith triethanol thermostable +17oWith, stearic acid +73oWith the polyethylene oxide 400 +15oC. the resulting reaction mixture triethanolamine stearate has a melting point of +80oC.Technology of production of ointments benzyl benzoate is as follows.The stearic acid is melted, then load into her benzyl benzoate and polyethylene oxide 400, per rastabilly, mix, keep the temperature (802)oC, then the solution is passed melt of stearic acid with benzyl benzoate and polyethylene oxide 400. After mixing the ointment is cooled and packaged.The order of input of an aqueous solution of triethanolamine stable in the melt of stearic acid with benzyl benzoate and polyethylene oxide 400 or Vice versa determined empirically. It is established that the ointment is a less viscous when entering the melt in an aqueous solution of triethanolamine. Experimentally selected feed rate of the melt and the intensity of mixing ointments.In the course of the research developed temperature process. Considered the possibility of mixing the melted oil phase with a temperature of 70oWith an aqueous phase having a temperature 20, 30, 40, 50, 60, 70, 80oC. it is Established that when the temperature of the aqueous phase of less than 75oWith the ointment obtained is non-uniform in the sample on a glass slide features include stearic acid in diameter from 1 to 3 mm, because when the temperature of one of the components below the 75oWith mixing, the temperature of the reaction mixture is reduced below the melting point of stearic acid +73oWith stearate and triethanolamine +80oWith so burnig range (802)oC. (table 1)
Theoretically and experimentally evaluated the possibility of optimizing the composition of the ointment with the aim of improving its technological properties, increase fluidity.Studied the effect of triethanolamine stearate on the viscosity of the ointment. Reducing the number of polyethylene oxide 400 did not affect the viscosity of the ointment, decrease the amount of fatty phase - stearic acid below 10 wt.% leads to a shift of the pH of the ointment in the alkaline side. (Table 2)
On the basis of the conducted research was developed optimal variant of the proposed composition of the ointment benzyl benzoate.Example 1.For the preparation of 300 kg 20% ointment benzyl benzoate 54 kg stearic acid is melted, download it 60,61 kg of benzyl benzoate and 15 kg of polyethylene oxide 400, stirred for 15-20 min, heated to a temperature (802)oC. In 155,39 l purified water load 15 kg of triethanolamine, mix, keep the temperature (802)oC, then the solution is passed melt of stearic acid with benzyl benzoate and polyethylene oxide 400, stirred, cooled, and passed on packing.Example 2.For the preparation of 300 kg 10% ointment benzyl benzoate 30 kg of stearic acid is melted, download it 30,3 kg Beznau water load 7.5 kg of triethanolamine, mix, keep the temperature (802)oWith, then the solution is passed melt of stearic acid with benzyl benzoate and polyethylene oxide 400, stirred, cooled, and passed on packing. The benzyl benzoate ointment easy to use, glides on skin without the use of tampons and saved it for 4-5 days, has a high therapeutic effect and is stable for 3 years.Sources of information
1. Mashkovsky M. D. Medicines. - Kharkov: Torgsin, 1998, S. 401.2. Encyclopedia of drugs. - Moscow, "radar-2000", 1999 Protivochesotocnaya medicinal product containing the active ingredient benzyl benzoate, emulsifier and water, wherein the tool is made in the form of ointment contains triethanolamine and stearic acid to obtain an emulsifier, and optionally contains a polyethylene oxide 400 in the following ratio, wt.%:
The benzyl benzoate - 10,0-20,0
Triethanolamine - 2,5-5,0
Stearic acid - 10,0-18,0
The polyethylene oxide 400 - 5,0
Purified water - Ostalnoe
< / BR>in which X represents-O - or -(CnH2n)-, in which n is 0, 1, 2 or 3; R1represents alkyl containing from 1 to 10 carbon atoms, or monocyclohexyl containing up to 10 carbon atoms; R2represents hydrogen, lower alkyl or lower alkoxy; R3represents (1) phenyl or naphthalene, unsubstituted or substituted by one or more than one Deputy each independently selected from nitro, halogeno, amino, amino substituted by alkyl containing 1-5 carbon atoms, alkyl containing up to 10 carbon atoms, cycloalkyl containing up to 10 carbon atoms, alkoxy containing up to 10 carbon atoms, cycloalkane containing up to 10 carbon atoms, phenyl or methylendioxy; (2) pyridine; each of R4and R5taken separately, represent hydrogen, or R4and R5taken together, represent a carbon-carbon bond; Y is-COZ, -CN or lower alkyl containing from 1 to 5 carbon atoms; Z represents R7represents an alkyl
FIELD: medicine, narcology.
SUBSTANCE: one should detect satisfaction insufficiency syndrome due to performing genetic analysis by the presence of, at least, one of the genes coding the exchange of neuromediators being the constituents of human satisfaction system. One should compensate satisfaction insufficiency due to performing, at least, one complex of physical exercises. Moreover, in case of availability of pathological gene allele of dopamine D2 receptor and/or protein gene of reverse dopamine capture in patient one should apply the complex of physical exercises including those to provide sedative effect, and in case of availability of pathological gene allele of dopamine-beta-hydroxylase protein one should apply the complex of physical exercises including those that induce an activating effect. In case of availability of pathological gene allele of dopamine D2 receptor and/or protein gene of reverse dopamine capture one should apply additional food biologically active additives based upon amino acids being the precursors of neuromediators, such as taurine, D-, L-phenylalanine in combination with 5-hydroxytryptophan, hypericin and vitamin B6, and in case of pathological gene allele of dopamine-beta-hydroxylase protein one should additionally apply food biologically active additives based upon amino acids being the precursors of neuromediators, such as: taurine, tyrosine and/or dimethylaminoethanol, lecithin and group B-vitamins. The present innovation enables to take into account pathological disease mechanism.
EFFECT: higher efficiency of prophylaxis.
14 cl, 5 ex